Attovia Therapeutics Inc., an early-stage drug developer focused on immune system diseases with high unmet need, raised $289 million in a US initial public offering that priced at the top of its marketed range.
Attovia Therapeutics Inc., an early-stage drug developer focused on immune system diseases with high unmet need, raised $289 million in a US initial public offering that priced at the top of its marketed range.
Lire l’article complet sur le site source
Bloomberg — Markets (EN)